We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $7.48B
1-Year Est. Return 104.76%
This Fund
S&P 500
This Quarter Est. Return
+21.54%
1 Year Est. Return
+104.76%
3 Year Est. Return
+313.12%
5 Year Est. Return
+388.67%
10 Year Est. Return
+3,437.54%
AUM
$6.08B
AUM Growth
+$375M
Cap. Flow
-$205M
Cap. Flow %
-3.37%
Top 10 Hldgs %
23.61%
Holding
263
New
25
Increased
137
Reduced
69
Closed
23

Top Buys

Rank Stock Value
1
SLNO
Soleno Therapeutics
SLNO
+$34.7M
2
TLN
Talen Energy Corp
TLN
+$29.8M
3
ABVX
Abivax
ABVX
+$24.3M
4
EVH icon
Evolent Health
EVH
+$21.4M
5
PLD icon
Prologis
PLD
+$16.2M

Top Sells

Rank Stock Value
1
VRNA
Verona Pharma
VRNA
+$212M
2
BPMC
Blueprint Medicines
BPMC
+$93.4M
3
WDAY icon
Workday
WDAY
+$28M
4
RELY icon
Remitly
RELY
+$27M
5
INSM icon
Insmed
INSM
+$23.4M

Sector Composition

Rank Sector Weight
1 Healthcare 37.53%
2 Industrials 18.58%
3 Technology 17.54%
4 Consumer Discretionary 8.04%
5 Utilities 5.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GH icon
1
Guardant Health
GH
$21.7B
$208M 3.41%
3,321,338
-137,625
-4% -$7.49M
MIRM icon
2
Mirum Pharmaceuticals
MIRM
$5.94B
$185M 3.04%
2,522,563
-114,922
-4% -$7.31M
XMTR icon
3
Xometry
XMTR
$5.39B
$170M 2.79%
3,117,906
-39,940
-1% -$1.73M
TT icon
4
Trane Technologies
TT
$98.8B
$168M 2.76%
398,521
+10,046
+3% +$4.29M
INSM icon
5
Insmed
INSM
$25.9B
$145M 2.38%
1,005,107
-191,387
-16% -$23.4M
LRCX icon
6
Lam Research
LRCX
$378B
$121M 1.99%
904,695
-92,202
-9% -$9.76M
IRTC icon
7
iRhythm Holdings
IRTC
$3.96B
$119M 1.96%
691,512
-61
-0% -$9.7K
GEV icon
8
GE Vernova
GEV
$243B
$118M 1.95%
192,698
-7,709
-4% -$4.67M
SRRK icon
9
Scholar Rock
SRRK
$7.04B
$104M 1.71%
2,799,456
-113,790
-4% -$3.98M
BBNX
10
Beta Bionics
BBNX
$887M
$98.5M 1.62%
4,957,252
+24,901
+0.5% +$438K
ARGX icon
11
argenx
ARGX
$64B
$92.5M 1.52%
125,371
-12
-0% -$7.91K
ROP icon
12
Roper Technologies
ROP
$42.2B
$90.7M 1.49%
181,906
-18
-0% -$9.6K
VST icon
13
Vistra
VST
$46B
$90.7M 1.49%
462,841
-23,201
-5% -$4.6M
AXSM icon
14
Axsome Therapeutics
AXSM
$10.4B
$90.6M 1.49%
746,398
+20,726
+3% +$2.33M
TOST icon
15
Toast
TOST
$20.3B
$90.6M 1.49%
2,481,575
+7,177
+0.3% +$312K
ODFL icon
16
Old Dominion Freight Line
ODFL
$41.2B
$85.4M 1.4%
606,679
+7,848
+1% +$1.2M
COLL icon
17
Collegium Pharmaceutical
COLL
$786M
$83.7M 1.38%
2,390,912
-250,489
-9% -$8.71M
DHI icon
18
D.R. Horton
DHI
$41.2B
$77.2M 1.27%
455,674
+13,684
+3% +$2.15M
URI icon
19
United Rentals
URI
$64.1B
$76.6M 1.26%
80,244
+373
+0.5% +$332K
VRNA
20
DELISTED
Verona Pharma
VRNA
$72.7M 1.19%
680,929
-2,034,395
-75% -$212M
WMB icon
21
Williams Companies
WMB
$90.2B
$68.9M 1.13%
1,085,237
+40,799
+4% +$2.39M
AJG icon
22
Arthur J. Gallagher & Co
AJG
$68.6B
$67.1M 1.1%
216,693
+6,122
+3% +$1.85M
ASML icon
23
ASML
ASML
$651B
$64M 1.05%
66,084
-1,377
-2% -$1.08M
TRGP icon
24
Targa Resources
TRGP
$61.7B
$63M 1.04%
375,619
+24,219
+7% +$4.03M
TMDX icon
25
Transmedics
TMDX
$3.07B
$61.4M 1.01%
547,296
-59
-0% -$6.91K
1
2 3 4 5

Similar funds

S
SignatureFD Atlanta, Georgia $7.49B AUM 24.82% 1-Year Est. Return
CCM
Check Capital Management Costa Mesa, California $7.52B AUM 15.3% 1-Year Est. Return
O
Ossiam Paris, France $7.54B AUM 50.81% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $7.43B AUM 24.49% 1-Year Est. Return
HPC
HM Payson & Co Portland, Maine $7.54B AUM 31.34% 1-Year Est. Return
FPP
Findlay Park Partners London, United Kingdom $7.41B AUM 26.32% 1-Year Est. Return
RIG
RiverFront Investment Group Richmond, Virginia $7.56B AUM 23.82% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $7.56B AUM 44.87% 1-Year Est. Return

Eventide Asset Management's Q3 2025 Portfolio in Review

As of Q3 2025, Eventide Asset Management held 263 positions worth $6.08B, up 6.6% from $5.71B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Eventide Asset Management withdrew a net $205M in Q3 2025, closing 23 positions and reducing 69 holdings. Its most notable exit was Blueprint Medicines, an estimated $93.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 38% of assets, up from 37% a quarter earlier, followed by Industrials and Technology.

Against the trend, Eventide Asset Management opened a new position in Soleno Therapeutics worth $31.6M.

  • Eventide Asset Management's largest Q3 2025 buy was Soleno Therapeutics: 467,435 shares worth $31.6M.
  • Eventide Asset Management added most to Talen Energy Corp in Q3 2025, an estimated $29.8M increase.
  • Eventide Asset Management's biggest Q3 2025 reduction was Verona Pharma, cutting an estimated $212M.
  • Eventide Asset Management fully exited Blueprint Medicines in Q3 2025, selling an estimated $93.4M.
  • Eventide Asset Management's ten largest holdings make up 24% of its $6.08B portfolio in Q3 2025.
  • Eventide Asset Management opened 25 new positions and closed 23 in Q3 2025.
  • Eventide Asset Management's portfolio value rose 6.6% quarter-over-quarter to $6.08B.

Based on Eventide Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.